Library · Muscle, bone & joint · Bone and tissue regeneration
TP508 (Chrysalin)
Chrysalin, TP508, Thrombin peptide 508, AGYKPDEGKRGDACEGDSGGPFV
A synthetic 23-amino-acid peptide, Chrysalin, derived from thrombin, discovered in the 1990s to mimic thrombin's tissue-repair effects without its clotting activity. Animal studies show benefits for bone fracture healing, soft tissue repair, and wound closure; human trials for diabetic foot ulcers and fracture healing were promising, but the compound has not reached regulatory approval.
Research score 80/100. Reference only, not a dose.
- Healing
- Anti-inflammatory
- Joint Support
- Bone Health
- Wound Healing
- US status
- Investigational
- Approval
- Clinical Trial - Completed
- Evidence
- Promotes tissue repair/revascularization (diabetic ulcers, fractures). FDA approved for new ARDS clinical trials.
- Research score
- 80 / 100
- Indication
- Wound Healing (Research)
- Origin
- USA
- Source category
- Muscles & Joints
- Status group
- Investigational
Mechanism
Binds the PAR-1 thrombin receptor to trigger angiogenesis, cell migration, and repair pathways, raising VEGF and PDGF, supporting bone-forming cell activity, curbing inflammation via NF-κB modulation, and enhancing bone mineralization and fracture healing through PI3K/Akt and MAPK signaling.
Safety file
Excellent safety record in human trials; no drug-related adverse events reported in diabetic foot ulcer or fracture studies, aside from possible mild injection-site reactions.
- Local injection site reactions
- Temporary inflammation
- Mild discomfort at application site